
**Background**: Breast cancer is the most common cancer among women in the United States. Newly diagnosed patients with breast cancer often experience anxiety, depression, and stress. However, the impact of psychological distress on healthcare resource utilization (HCRU) and costs has not been adequately assessed.

**Objectives**: To evaluate the incidence and prevalence of anxiety, depression, and stress reaction/adjustment disorder among patients newly diagnosed with breast cancer, to examine HCRU and costs, and to assess the association of these psychiatric disorders with costs.

**Methods**: This retrospective observational cohort study was conducted using a large US administrative claims database with an index date of newly diagnosed breast cancer. Demographics and comorbidities (including anxiety, depression, and stress reaction/adjustment disorder) were assessed using data collected 12 months before and after the index date. HCRU and costs were assessed using data collected 12 months after the index date. Generalized linear regressions were performed to examine the association between healthcare costs and anxiety, depression, and stress reaction/adjustment disorder.

**Results**: Of 6392 patients with newly diagnosed breast cancer, 38.2% were diagnosed with psychiatric disorders including anxiety (27.7%), depression (21.9%), or stress reaction/adjustment disorder (6%). The incidence of these psychiatric disorders was 15% and the prevalence was 23.2%. Patients with anxiety, depression, or stress reaction/adjustment disorder had higher rates of several types of HCRU \( P < .0001 \) and higher total all-cause costs compared with patients without these psychiatric disorders \( P < .0001 \). Patients with incident anxiety, depression, or stress reaction/adjustment disorder incurred higher all-cause costs in the first year following breast cancer diagnosis than those with prevalent anxiety, depression, or stress reaction/adjustment disorder \( P < .0003 \), or those without these psychiatric disorders \( P < .0001 \).

**Discussion**: Of patients with anxiety, depression, or stress reaction/adjustment disorder, those with incident psychiatric disorders had higher healthcare costs, suggesting that new-onset psychological distress may contribute to higher costs incurred by the payer. Timely treatment of psychiatric disorders in this population may improve clinical outcomes and reduce HCRU and costs.

**Conclusions**: Anxiety, depression, and stress reaction/adjustment disorder were common among patients newly diagnosed with breast cancer and were associated with increased healthcare costs in the first year following breast cancer diagnosis.

**ARTICLE INFORMATION**

*Article history:* Received December 2, 2022, Received in revised form February 3, 2023, Accepted February 6, 2023

*Keywords:* cancer-related distress, anxiety, depression, adjustment disorder, healthcare resource utilization, healthcare costs, claims database analysis

*Corresponding author:* Email address: mmalecki@bluenotetx.com

> Supplementary Material

**ABSTRACT**

**Background**: Breast cancer is the most common cancer among women in the United States. Newly diagnosed patients with breast cancer often experience anxiety, depression, and stress. However, the impact of psychological distress on healthcare resource utilization (HCRU) and costs has not been adequately assessed.

**Objectives**: To evaluate the incidence and prevalence of anxiety, depression, and stress reaction/adjustment disorder among patients newly diagnosed with breast cancer, to examine HCRU and costs, and to assess the association of these psychiatric disorders with costs.

**Methods**: This retrospective observational cohort study was conducted using a large US administrative claims database with an index date of newly diagnosed breast cancer. Demographics and comorbidities (including anxiety, depression, and stress reaction/adjustment disorder) were assessed using data collected 12 months before and after the index date. HCRU and costs were assessed using data collected 12 months after the index date. Generalized linear regressions were performed to examine the association between healthcare costs and anxiety, depression, and stress reaction/adjustment disorder.

**Results**: Of 6392 patients with newly diagnosed breast cancer, 38.2% were diagnosed with psychiatric disorders including anxiety (27.7%), depression (21.9%), or stress reaction/adjustment disorder (6%). The incidence of these psychiatric disorders was 15% and the prevalence was 23.2%. Patients with anxiety, depression, or stress reaction/adjustment disorder had higher rates of several types of HCRU \( P < .0001 \) and higher total all-cause costs compared with patients without these psychiatric disorders \( P < .0001 \). Patients with incident anxiety, depression, or stress reaction/adjustment disorder incurred higher all-cause costs in the first year following breast cancer diagnosis than those with prevalent anxiety, depression, or stress reaction/adjustment disorder \( P < .0003 \), or those without these psychiatric disorders \( P < .0001 \).

**Discussion**: Of patients with anxiety, depression, or stress reaction/adjustment disorder, those with incident psychiatric disorders had higher healthcare costs, suggesting that new-onset psychological distress may contribute to higher costs incurred by the payer. Timely treatment of psychiatric disorders in this population may improve clinical outcomes and reduce HCRU and costs.

**Conclusions**: Anxiety, depression, and stress reaction/adjustment disorder were common among patients newly diagnosed with breast cancer and were associated with increased healthcare costs in the first year following breast cancer diagnosis.

**BACKGROUND**

Breast cancer is the most common cancer among women in the United States, accounting for about 30% of all new female cancers recorded each year. With advancements in early screening, diagnosis, and breakthrough treatments, 5-year breast cancer survival rates continue to improve, ranging from 40% in low-income countries to 80% in developed countries. Although the quality of life of patients with breast cancer
cancer has also improved over time,\textsuperscript{1,4} quality of life is lower for pa-
tients undergoing treatment compared with those who have completed
treatment,\textsuperscript{7} likely due to various treatment-related symptoms (eg, pain,
worry, sexual dysfunction).\textsuperscript{5}

Patients with cancer also commonly experience anxiety, depres-
son, and/or stress reaction/adjustment disorder; however, the reported
prevalence of these forms of distress varies widely.\textsuperscript{7} In patients with
early-stage breast cancer, the prevalence of moderate to severe anxi-
ey, depression, and stress was found to be 26.2\%, 31.8\%, and 36\%,
respectively.\textsuperscript{6} The emotional distress and associated psychi-
atriac disorders experienced by patients with cancer often go unrecognized and
untreated by healthcare providers,\textsuperscript{7} likely due to limited time and in-
sufficient training in screening and management of emotional distress
and related disorders.\textsuperscript{6,9} Nevertheless, distress and psychiatric disorders
affect a range of key oncology health outcomes. These include lower
medication adherence and persistence, and treatment engagement and
effectiveness, which can increase both morbidity and mortality.\textsuperscript{10,11}

Clinical guidelines for the treatment of anxiety, depression, and
adjustment disorders in patients with cancer recommend a compre-
hensive approach to care that incorporates both pharmacologic and
psychosocial interventions.\textsuperscript{12-14} Pharmacologic decision-making should
balance benefits of treatment with the potential for adverse effects,
poor tolerability, and possible drug interactions.\textsuperscript{15} Antidepressant
medication may be reserved for patients with more moderate to se-
vere symptoms, with a focus on selective serotonin reuptake inhibitors
due to their tolerability and lower potential for drug interactions.\textsuperscript{15}
However, antidepressants that are potent CYP2D6 inhibitors are not
recommended in combination with tamoxifen,\textsuperscript{17} and long-term use of
benzodiazepines for the treatment of anxiety should also be avoided.\textsuperscript{12}
Psychosocial interventions that are recommended by oncology clinical
guidelines range from low-intensity interventions, such as psychoed-
ucation, self-help programs, and group-based peer support, to more
structured evidence-based treatments, such as behavioral activation,
cognitive behavioral therapy, and interpersonal therapy.\textsuperscript{12,14}

Psychological distress creates an increased economic burden on
patients and the healthcare system,\textsuperscript{13,16} which currently lacks the
resources to address the psychological needs of patients with cancer.
Specifically, adequate psychological staffing in cancer centers is highly
variable, with an average of 2523 newly registered patients per year for
each full-time psychologist.\textsuperscript{17} Moreover, patients report poor access to
specialized psycho-oncological care.\textsuperscript{10} Due to limited access to appro-
priate care, the economic burden is a consequence of increased health-
care resource utilization (HCRU) in other areas, such as emergency
department (ED) visits, outpatient visits, inpatient admissions, mental
health services, and primary care physician/provider (PCP) visits.\textsuperscript{15,16}

This article reports on the incidence and prevalence of anxiety,
depression, and stress reaction/adjustment disorders among newly
diagnosed patients with breast cancer and investigates their impact on
HCRU and healthcare costs.

Objectives

Currently, there is limited real-world evidence regarding the impact
of anxiety, depression, and stress reaction/adjustment disorder among
newly diagnosed patients with breast cancer on HCRU and healthcare
costs. Therefore, the objectives of this study were: (1) to evaluate the
incidence and prevalence of anxiety, depression, and stress reaction/adj-
justment disorder among patients newly diagnosed with breast cancer;
(2) to examine all-cause HCRU and costs, and mental health–related
HCRU and costs, among patients newly diagnosed with breast can-
cer, and compare them between patients with vs without psychiatric
disorders and between patients with incident vs prevalent psychiatric
disorders; and (3) to assess the association between healthcare costs and
anxiety, depression, and stress reaction/adjustment disorder among pa-
tients newly diagnosed with breast cancer.

METHODS

Study Design

This was a retrospective observational cohort study of newly diagnosed
patients with breast cancer using Aetna administrative claims data from
January 1, 2017, to December 31, 2020 (study period), representing
one part of a retrospective study of comorbid psychiatric disorders in
breast cancer within a managed care system. Details of the study de-
sign and data source have been published previously.\textsuperscript{20} Detailed inclu-
sion and exclusion criteria are described in Supplementary Figure S1.
The database includes over 20 million Aetna members and contains
patient-level data including inpatient and outpatient data, and medi-
cal and pharmacy claims of fully insured commercial health plan and
Medicare Advantage members. All data handling complied with federal
and state requirements, and the privacy and security of individually
identifiable personal health information were preserved as required by
Health Insurance Portability and Accountability Act (HIPAA) stan-
dards. The study was approved by the Sterling Institutional Review
Board (Atlanta, Georgia) prior to initiation. The reporting of this study
conforms to the STROBE guidelines for observational cohort studies.\textsuperscript{21}

Patients with breast cancer were identified between January 1,
2018, and December 31, 2019 (index period), by International Clas-
ification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM:
C50.x) codes. The index date was defined as the earliest diagnosis date
of breast cancer within the index period. The baseline period consisted of
at least 12 months of continuous medical and pharmacy coverage
prior to the index date, and the follow-up period consisted of at least
12 months of continuous medical and pharmacy coverage post-index
date (Figure 1). Breast cancer was defined as (1) 1 hospitalization with
case-defining breast cancer (ICD-10-CM: C50.x) in the first diagnostic
position (primary diagnosis), or (2) 1 hospitalization with a Z code in-
dicating radiotherapy (Z51.12) in the first diagnostic position and any
case-defining diagnosis of breast cancer (C50.x) in the second diagno-
sic position, or (3) 3 or more outpatient medical encounters occurring
within a 90-day period with any case-defining diagnoses of breast can-
cer (C50.x) in the first or second diagnostic position.\textsuperscript{22}

The demographic characteristics of patients included age at index
date; US geographic region (Midwest, Northeast, South, and West);
rural, suburban, or urban residence; and median household income.
Household income was estimated by merging 2010 US Census data
with the claims data using zip codes. Comorbid conditions were as-
sessed using all available data (any inpatient and outpatient claims)
prior to and including the index date. All conditions were defined us-
ing previously described methods based on ICD-10-CM codes.\textsuperscript{23-25} The
Charlson Comorbidity Index,\textsuperscript{26} a validated approach that summariz-
es disease burden and predicts risks of mortality and high healthcare
costs,\textsuperscript{27-29} was also calculated.

Anxiety (F40.x [phobic anxiety disorders], F41.x [other anxiety
disorders]), depression (F32.x [major depressive disorder, single epi-
isode], F33.x [major depressive disorder, recurrent]), and stress reac-
tion/adjustment disorder (F43.x [reaction to severe stress, and adjust-
ment disorders]) were identified using ICD-10-CM codes in the claims
data. Incident cases were defined as patients with anxiety, depression,
or stress reaction/adjustment disorder during the 1-year follow-up pe-
riod, without any diagnosis of anxiety, depression, or stress reaction/
adjustment disorder during the 1-year baseline period. Prevalent cases
were defined as patients with any evidence of anxiety, depression, or
stress reaction/adjustment disorder in the 1-year follow-up period and
the 1-year baseline period.
All-cause HCRU and costs were assessed using all medical claims and pharmacy claims and were aggregated over the 12-month follow-up period. HCRU included any ED visits, outpatient visits, mental health services, inpatient admissions, and length of stay (LOS) among those with inpatient admissions. Mental health–related HCRU and costs were assessed using medical claims identified with a primary diagnosis of anxiety, depression, or stress reaction/adjustment disorder, or pharmacy claims identified with depression-, anxiety-, or stress reaction/adjustment disorder–related medications within the follow-up period. All healthcare costs reported in this study refer to allowed costs (total amount paid by the payer), and were inflated to 2020 US dollars using the medical care services component of the Consumer Price Index.27

**Statistical Analysis**
Continuous and categorical data were expressed as means (± SD) and relative frequencies (%), respectively. Statistical significance was assessed with Student’s t-test, or Wilcoxon rank-sum test for continuous variables, and χ² tests for categorical variables. To evaluate the association between anxiety, depression, and stress reaction/adjustment disorder and healthcare costs, multivariable generalized linear regression models were performed to calculate adjusted cost ratios with corresponding 95% confidence intervals and incremental cost differences. Age, geographic region, rural/suburban/urban residence, household income, payer type, surgery year, number of comorbid conditions, number of cancer-related therapies, and previous year total all-cause healthcare costs were controlled for. Log-transformation and gamma distribution were applied based on the distribution and presence of heteroskedasticity. Log link was chosen as it has been found to best specify the relationship between cost and explanatory variables.28 All P values were 2-sided, with P < .05 considered statistically significant. All data management and statistical analyses were conducted using SAS version 9.4 statistical software (SAS Institute Inc., Cary, North Carolina).

**RESULTS**
A total of 6392 patients with newly diagnosed breast cancer were included in the study (Supplementary Figure S1). The average (SD) age was 67.43 (12.23) years. The baseline median household income, percentage of commercial and Medicare insurance payers, and the number of comorbid conditions are presented in the baseline patient characteristics (Supplementary Table S1).

**Objective 1: Incidence and Prevalence of Comorbid Psychiatric Disorders**
In this population, the incidence of anxiety, depression, or stress reaction/adjustment disorder was 15% (n = 959), and the prevalence was 23.2% (n = 1485). Overall (including both incident and prevalent cases), 38.2% (n = 2444) of patients with newly diagnosed breast cancer experienced anxiety, depression, or stress reaction/adjustment disorder during the 1-year follow-up period. Anxiety was the most common of the 3 types of psychiatric disorders, observed in 27.7% of patients during the first year following breast cancer diagnosis. Depression was observed in 21.9% of patients, and stress reaction/adjustment disorder was observed in just 6% of patients (Figure 2).

**Objective 2: All-Cause and Mental Health–Related HCRU and Costs**
During the first year following breast cancer diagnosis, patients with anxiety, depression, or stress reaction/adjustment disorder were significantly more likely to see their PCP (94.84% vs 88.98%, P < .0001), visit the ED (34.12% vs 22.92%; P < .0001), and incur an inpatient admission (28.31% vs 18.29%; P < .0001) compared with patients without these psychiatric disorders. They also had significantly longer LOS for inpatient admissions (mean [SD] days: 2.23 [6.28] vs 1.06 [3.99]; P < .0001) compared with patients without anxiety, depression, or stress reaction/adjustment disorder. Additionally, patients with anxiety, depression, or stress reaction/adjustment disorder were more likely to see a specialist (99.14% vs 97.44%, P < .0001), have a psychiatry visit (5.32% vs 0.20%, P < .0001), and engage in any mental health services (16.65% vs 0.73%, P < .0001) than patients without these psychiatric disorders (Table 1).

When comparing patients with new onset psychiatric disorders (ie, incident) vs those with pre-existing psychiatric disorders (ie, prevalent), patients with incident psychiatric disorders had higher rates of inpatient admissions (30.87% vs 26.67%, P = .0273), whereas patients with prevalent psychiatric disorders had higher rates of PCP visits (95.96% vs 93.12%, P = .0026). Rates of ED visits were similar between these 2 patient groups, as was average LOS for inpatient admissions. Regarding specialty care, overall rates of specialist visits were similar, but patients with prevalent psychiatric disorders had higher rates...
of psychiatry visits (7.07% vs 2.61%, \(P < .0001\)). Rates of any mental health services were similar between these 2 patient groups (Table 1).

During the first year following breast cancer diagnosis, patients with anxiety, depression, or stress reaction/adjustment reaction incurred significantly higher average costs for ED visits ($1146 [2806] vs $598 [1936] per patient per year [PPPY]; \(P < .0001\)), inpatient admissions ($8394 [23123] vs $4496 [15671] PPPY; \(P < .0001\)), and specialist visits ($8738 [23938] vs $6846 [21963] PPPY; \(P < .0001\)) compared with patients without these psychiatric disorders. On average, total medical costs ($65594 [90999] vs $52212 [78397] PPPY; \(P < .0001\)), total pharmacy costs ($6628 [25091] vs $5199 [19797] PPPY; \(P < .0001\)), and total healthcare costs ($72223 [94643] vs $57411 [81088] PPPY; \(P < .0001\)) were significantly higher for patients with anxiety, depression, or stress reaction/adjustment disorder than patients without these psychiatric disorders (Table 2).

When comparing patients with incident and prevalent psychiatric disorders, patients with incident psychiatric disorders incurred higher average costs for inpatient admissions ($9347 [24240] vs $7778 [22358] PPPY; \(P = .0232\)) and specialist visits ($10914 [28831] vs $7333 [20042] PPPY; \(P < .0001\)), whereas patients with prevalent psychiatric disorders incurred higher average costs for PCP visits ($1170 [5133] vs $946 [2912] PPPY; \(P = .0010\)). Average costs for ED visits were similar. On average, total medical costs ($79096 [105686] vs $56875 [78915] PPPY; \(P < .0001\)) and total healthcare costs ($85535 [108568] vs $63627 [83361] PPPY; \(P < .0001\)) were significantly higher for patients with incident psychiatric disorders, whereas total pharmacy costs ($6751 [26631] vs $6438 [22513] PPPY; \(P < .0001\)) were significantly higher for patients with prevalent psychiatric disorders (Table 2).

Regarding mental health–related costs, patients with anxiety, depression, or stress reaction/adjustment disorder incurred significantly higher average costs for any mental health services than patients without these psychiatric disorders ($708 [2616] vs $33 [259] PPPY; \(P < .0001\)). Among patients with anxiety, depression, or stress reaction/adjustment disorder, patients with prevalent psychiatric disorders incurred higher average costs for inpatient admissions ($9347 [24240] vs $7778 [22358] PPPY; \(P = .0232\)) and specialist visits ($10914 [28831] vs $7333 [20042] PPPY; \(P < .0001\)), whereas patients with prevalent psychiatric disorders incurred higher average costs for PCP visits ($1170 [5133] vs $946 [2912] PPPY; \(P = .0010\)). Average costs for ED visits were similar. On average, total medical costs ($79096 [105686] vs $56875 [78915] PPPY; \(P < .0001\)) and total healthcare costs ($85535 [108568] vs $63627 [83361] PPPY; \(P < .0001\)) were significantly higher for patients with incident psychiatric disorders, whereas total pharmacy costs ($6751 [26631] vs $6438 [22513] PPPY; \(P < .0001\)) were significantly higher for patients with prevalent psychiatric disorders (Table 2).

### Table 1. Healthcare Resource Utilization Among Patients With Breast Cancer in the First Year Following Diagnosis

<table>
<thead>
<tr>
<th>Table 1. Healthcare Resource Utilization Among Patients With Breast Cancer in the First Year Following Diagnosis</th>
<th>No Psychiatric Disorders (n = 3948)</th>
<th>Psychiatric Disorders (n = 2444)</th>
<th>(P) Value(^{a})</th>
<th>Psychiatric Disorders</th>
<th>(P) Value(^{b})</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All-cause HCRU</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any inpatient admission, n (%)</td>
<td>722 (18.29)</td>
<td>692 (28.31)</td>
<td>&lt;.0001</td>
<td>296 (3.87)</td>
<td>396 (26.67)</td>
</tr>
<tr>
<td>Any ED visit, n (%)</td>
<td>905 (22.92)</td>
<td>834 (34.12)</td>
<td>&lt;.0001</td>
<td>322 (33.58)</td>
<td>512 (34.48)</td>
</tr>
<tr>
<td>PCP visit, n (%)</td>
<td>3513 (88.98)</td>
<td>2318 (94.84)</td>
<td>&lt;.0001</td>
<td>893 (93.12)</td>
<td>1425 (95.96)</td>
</tr>
<tr>
<td><strong>Specialist visit, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncologist</td>
<td>2889 (73.18)</td>
<td>1838 (75.20)</td>
<td>.0737</td>
<td>772 (8.50)</td>
<td>1066 (71.78)</td>
</tr>
<tr>
<td>Surgeon</td>
<td>2200 (55.72)</td>
<td>1466 (59.98)</td>
<td>.0009</td>
<td>602 (62.77)</td>
<td>864 (58.18)</td>
</tr>
<tr>
<td>Psychiatrist</td>
<td>8 (0.20)</td>
<td>130 (5.32)</td>
<td>&lt;.0001</td>
<td>25 (2.61)</td>
<td>105 (7.07)</td>
</tr>
<tr>
<td>Other specialists</td>
<td>3747 (94.91)</td>
<td>2377 (97.26)</td>
<td>&lt;.0001</td>
<td>932 (97.18)</td>
<td>1445 (97.31)</td>
</tr>
<tr>
<td><strong>Overall</strong></td>
<td>3847 (97.44)</td>
<td>2423 (99.14)</td>
<td>&lt;.0001</td>
<td>952 (99.27)</td>
<td>1471 (99.06)</td>
</tr>
<tr>
<td>LOS, mean (SD)</td>
<td>1.06 (3.99)</td>
<td>2.23 (6.28)</td>
<td>&lt;.0001</td>
<td>2.26 (5.83)</td>
<td>2.21 (6.56)</td>
</tr>
<tr>
<td>Any mental health services</td>
<td>29 (0.73)</td>
<td>407 (16.65)</td>
<td>&lt;.0001</td>
<td>149 (15.54)</td>
<td>258 (17.37)</td>
</tr>
</tbody>
</table>

\(^{a}\)Psychiatric disorders include anxiety, depression, and stress reaction/adjustment disorders.

\(^{b}\)Abbreviations: ED, emergency department; HCRU, healthcare resource utilization; LOS, length of stay; PCP, primary care provider/physician.

\(^{c}\)No psychiatric disorders vs psychiatric disorders.

\(^{d}\)Incident vs prevalent.
costs for any mental health services than patients with incident psychiatric disorders ($868 [3105] vs $459 [1554] PPPY; \( P < .0001 \); Table 2).

All-cause HCRU and costs for incident and prevalent anxiety, depression, and stress reaction/adjustment disorder are provided in Supplementary Table S2.

**Objective 3: Association Between Healthcare Costs and Anxiety, Depression, and Stress Reaction/Adjustment Disorder**

Patients with breast cancer who had incident anxiety, depression, or stress reaction/adjustment disorder incurred higher all-cause healthcare costs in the first year following breast cancer diagnosis than those with prevalent anxiety, depression, or stress reaction/adjustment disorder, or those with none of these psychiatric disorders (adjusted cost ratio: 1.20 [1.11-1.29], \( P < .0001 \), 1.34 [1.25-1.43], \( P < .0001 \), respectively; Figure 3). The predicted incremental total all-cause cost difference in the 1-year period after breast cancer diagnosis between incident psychiatric disorders and prevalent psychiatric disorders was $25778 PPPY, and the incremental total all-cause cost difference between incident psychiatric disorders and no psychiatric disorders was $31891 PPPY (Figure 4). A similar trend was also observed when considering anxiety, depression, and stress reaction/adjustment disorder individually (Figures 3 and 4).

**DISCUSSION**

Our study included a large and representative sample, drawn from one of the largest national commercially insured and Medicare Advantage populations in the United States, representing over 20 million enrollees and providing a 1-year baseline and 1-year follow-up period. To our knowledge, this study is the first to assess the incidence and prevalence of anxiety, depression, and stress reaction/adjustment disorder among patients newly diagnosed with breast cancer and their impact on HCRU and costs. According to our study, a significant proportion of patients experienced anxiety, depression, or stress reaction/adjustment disorder during the first year following breast cancer diagnosis. Although rates of anxiety, depression, and stress among patients with breast cancer vary widely throughout the literature, our findings suggest that the rate of anxiety observed in the present study was comparable to estimates for early-stage breast cancer, whereas depression and stress reaction/adjustment disorder were observed in a smaller proportion of patients in the present study.

A significantly higher proportion of patients with anxiety, depression, or stress reaction/adjustment disorder had inpatient admissions, ED visits, PCP visits, psychiatry visits, mental health services visits, or other specialist visits, and significantly longer LOS compared with patients without these psychiatric disorders. Similarly, the costs of ED visits, inpatient admissions, PCP visits, specialist visits, and total medical and pharmacy expenses were higher for patients with anxiety, depression, or stress reaction/adjustment disorder compared with patients without these psychiatric disorders. Overall, anxiety, depression, and stress reaction/adjustment disorder were associated with increased costs among patients with breast cancer, as evidenced by significantly higher all-cause healthcare costs with the exception of prevalent depression.

Patients with breast cancer who experienced incident anxiety, depression, or stress reaction/adjustment disorder had higher all-cause healthcare costs than those with prevalent diagnoses of these psychiatric disorders or those without these disorders in the first year following breast cancer diagnosis. The higher healthcare costs incurred by patients with incident psychiatric disorders compared with prevalent psychiatric disorders suggest that new-onset anxiety or depression may contribute to higher costs incurred by the payer. Early psychosocial intervention has not only been found to be effective in improving clinical outcomes, but also leads to cost savings in the long term.23

The comparison of patients with incident and prevalent anxiety, depression, and stress reaction/adjustment disorder yielded interesting findings regarding potential treatment patterns. Specifically, patients

---

### Table 2. Healthcare Costs Among Patients with Breast Cancer in the First Year Following Diagnosis

<table>
<thead>
<tr>
<th></th>
<th>No Psychiatric Disorders (n = 948)</th>
<th>Psychiatric Disorders (n = 2444)</th>
<th>( P \text{Value}^{c} )</th>
<th>Psychiatric Disorders (n = 1485)</th>
<th>( P \text{Value}^{b} )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inpatient admissions</td>
<td>4496 (15671)</td>
<td>8393 (23123)</td>
<td>(&lt; .0001)</td>
<td>9347 (24240)</td>
<td>7778 (22358)</td>
</tr>
<tr>
<td>ED visit</td>
<td>598 (1936)</td>
<td>1146 (2806)</td>
<td>(&lt; .0001)</td>
<td>1282 (3310)</td>
<td>1058 (2423)</td>
</tr>
<tr>
<td>PCP visit</td>
<td>794 (6561)</td>
<td>1082 (4398)</td>
<td>(&lt; .0001)</td>
<td>946 (2912)</td>
<td>1170 (5133)</td>
</tr>
<tr>
<td>Specialist visit</td>
<td>6846 (21963)</td>
<td>8738 (23938)</td>
<td>(&lt; .0001)</td>
<td>10914 (28831)</td>
<td>7333 (20042)</td>
</tr>
<tr>
<td>Total medical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast cancer chemotherapy</td>
<td>5830 (30598)</td>
<td>8053 (38297)</td>
<td>(&lt; .0001)</td>
<td>11838 (51699)</td>
<td>5608 (25997)</td>
</tr>
<tr>
<td>Breast cancer radiotherapy</td>
<td>3491 (11193)</td>
<td>3655 (12861)</td>
<td>(&lt; .0001)</td>
<td>4201 (14430)</td>
<td>3302 (11729)</td>
</tr>
<tr>
<td>Breast cancer immunotherapy</td>
<td>2008 (17213)</td>
<td>2549 (19163)</td>
<td>(&lt; .0001)</td>
<td>3674 (24034)</td>
<td>1822 (15174)</td>
</tr>
<tr>
<td>Breast cancer surgery</td>
<td>4792 (6381)</td>
<td>5547 (7535)</td>
<td>(&lt; .0001)</td>
<td>6403 (8481)</td>
<td>4995 (6800)</td>
</tr>
<tr>
<td>Other surgery</td>
<td>4054 (7027)</td>
<td>5263 (8942)</td>
<td>(&lt; .0001)</td>
<td>6285 (8832)</td>
<td>4602 (8254)</td>
</tr>
<tr>
<td>Pain/fatigue/nausea/vomiting-related costs</td>
<td>85 (675)</td>
<td>246 (1832)</td>
<td>(&lt; .0001)</td>
<td>262 (1692)</td>
<td>235 (1901)</td>
</tr>
<tr>
<td>Any mental health services</td>
<td>33 (259)</td>
<td>708 (2616)</td>
<td>(&lt; .0001)</td>
<td>459 (1554)</td>
<td>868 (3105)</td>
</tr>
<tr>
<td>Other medical costs</td>
<td>31916 (52003)</td>
<td>39517 (57647)</td>
<td>(&lt; .0001)</td>
<td>45970 (61720)</td>
<td>35439 (54478)</td>
</tr>
<tr>
<td>Overall</td>
<td>52212 (78397)</td>
<td>65594 (90999)</td>
<td>(&lt; .0001)</td>
<td>79096 (105686)</td>
<td>56875 (78915)</td>
</tr>
<tr>
<td>Total pharmacy</td>
<td>5199 (19797)</td>
<td>6628 (25091)</td>
<td>(&lt; .0001)</td>
<td>6438 (22513)</td>
<td>6751 (26631)</td>
</tr>
<tr>
<td>Total healthcare costs</td>
<td>57411 (81088)</td>
<td>72223 (94646)</td>
<td>(&lt; .0001)</td>
<td>85535 (108568)</td>
<td>63627 (83361)</td>
</tr>
</tbody>
</table>

Psychiatric disorders include anxiety, depression, and stress reaction/adjustment disorders.

Abbreviations: ED, emergency department; HCRU, healthcare resource utilization; PCP, primary care provider/physician.

\( ^{c} \)No psychiatric disorders vs psychiatric disorders.

\( ^{b} \)Incident vs prevalent.
with prevalent psychiatric disorders had higher rates of PCP visits and psychiatry visits compared with patients with incident psychiatric disorders. These results suggest that patients with pre-existing psychological distress may have already established care with a PCP or psychiatrist for medication management. Although rates of any mental health services were similar between these 2 patient groups, patients with prevalent psychiatric disorders incurred higher average costs for any mental health services. This may suggest that both patients with pre-existing and new-onset psychological distress are equally amenable to engaging in mental health services following breast cancer diagnosis, but patients with prevalent psychiatric disorders may seek care more frequently or may have more complex visits, resulting in higher costs. Additionally, total pharmacy costs were significantly higher for patients with prevalent psychiatric disorders, suggesting again that these patients may have already established care for medication management, resulting in higher total pharmacy costs.

Overall, patients who experienced anxiety, depression, or stress reaction/adjustment disorder following breast cancer diagnosis may
represent a vulnerable population with unmet needs. Left untreated, psychological distress in patients with cancer could increase the morbidity of the disease and negatively affect patients' clinical outcomes and survival.\textsuperscript{10,11} Furthermore, distress and psychiatric disorders have an impact on treatment engagement and effectiveness, which in turn may increase HCRU and economic burden.\textsuperscript{10,11}

To diminish the burden of psychological distress, improve clinical outcomes, and reduce healthcare costs, viable treatment options for psycho-oncological distress are needed. In addition to addressing the unmet needs of patients with breast cancer who experience new-onset psychiatric disorders, effective treatments are also needed for patients whose pre-existing psychiatric disorders may be exacerbated by breast cancer diagnosis and treatment. Moreover, multiple comorbidities are common among patients with breast cancer and are associated with increased risk of anxiety and depression in the first year following breast cancer diagnosis.\textsuperscript{19} Due to limited availability of specialized psychological care for patients with cancer,\textsuperscript{17,18} there is a growing need for new treatment modalities, such as digital therapeutics. A recent review suggests that digital therapeutics in oncology possess clinical value, provide benefits perceived by both patients and healthcare providers, and may have a positive impact on HCRU, although further research is needed.\textsuperscript{20}

In addition, future studies are warranted to support the early identification of newly diagnosed patients with breast cancer who are at elevated risk of clinically meaningful psychological distress within the first year following diagnosis. While there is no algorithm or predictive model currently available to identify patients with breast cancer who are at high risk of anxiety, depression, or stress reaction/adjustment disorder, the results of this study may inform the development of a tool to aid clinicians in the early identification of at-risk patients, providing an opportunity to improve clinical outcomes and reduce HCRU and costs. Other avenues for future research could include the exploration of different methodologies and their impact on results. For example, whereas the present study utilized the widely used Charlson Comorbidity Index, future research may consider using a cancer-specific comorbidity index, such as the National Cancer Institute comorbidity index.\textsuperscript{31,52}

It is important to note that all studies using healthcare administrative claims data have inherent limitations. To begin with, only Aetna plan members were included in the present study. Consequently, the results of this analysis and their implications may not be generalizable to the overall population, especially those with other types of health insurance and the uninsured population. Next, there may be certain information not available in claims data that could have influenced study outcomes, such as clinical and disease-specific parameters, which may result in residual confounding. For example, disease severity could explain the outcomes of the present study in that late-stage breast cancer could result in increased psychological distress, increased HCRU, and increased spending. Additionally, although high out-of-pocket costs constitute financial toxicity to patients,\textsuperscript{35} our study did not capture healthcare costs incurred by patients. Patients may not have accessed mental health care due to high costs or other more urgent medical conditions.

Another limitation of the present study is that anxiety, depression, and stress reaction/adjustment disorder were identified using ICD-10-CM codes only. Therefore, the incidence and prevalence of these disorders may have been underestimated. Additionally, the 1-year baseline period utilized to classify patients as having no previous history of psychiatric disorders (ie, incident) may have excluded patients who were diagnosed prior to that time. Therefore, among patients in this study, the incidence of these disorders may have been overstated to the extent that the prevalence may have been underestimated. A significant proportion of patients with cancer report psychological distress (30%), but only a third of them (10%) seek medical attention for psychological distress.\textsuperscript{59} Limited accessibility and availability of mental health services for patients with cancer is one reason why the proportion of patients seeking these services may be low.\textsuperscript{59} In addition, patients with cancer may not be interested in reporting psychological distress to their healthcare providers,\textsuperscript{59} or receiving psycho-oncological services for psychological distress.\textsuperscript{37}

**CONCLUSIONS**

Anxiety, depression, and stress reaction/adjustment disorder are common among patients with newly diagnosed breast cancer and are significantly associated with increased HCRU and expenditures in the first year following breast cancer diagnosis. Patients with breast cancer who experienced incident anxiety, depression, or stress reaction/adjustment disorder had higher all-cause healthcare costs in the year following their cancer diagnosis than those with prevalent anxiety, depression, or stress reaction/adjustment disorder or none of these psychiatric disorders. Early diagnosis and optimized management of anxiety, depression, and stress reaction/adjustment disorder in this vulnerable population could improve clinical outcomes and reduce HCRU and healthcare costs.

**Acknowledgments:** Manuscript writing support was provided by Shilpa Chennakrishnaiah, PhD, and Elizabeth Hubscher, PhD, from Cytel, Inc., which was funded by Blue Note Therapeutics, Inc.

**Disclosures:** D.D. and H.C. report employment by CVS Health Corp., Woonsocket, Rhode Island, which conducted research funded by Blue Note Therapeutics, Inc. S.Z. and M.M. report employment by and stock in Blue Note Therapeutics, Inc.

**Funding:** This study was supported by Blue Note Therapeutics, Inc. Manuscript writing support was provided by Shilpa Chennakrishnaiah, PhD, and Elizabeth Hubscher, PhD, from Cytel, Inc., which was funded by Blue Note Therapeutics, Inc.

**REFERENCES**


8. Niedzwiedz CL, Katikireddi SV, Smith DJ. The extent that the prevalence may have been underestimated. A significant proportion of patients with cancer report psychological distress (30%), but only a third of them (10%) seek medical attention for psychological distress.\textsuperscript{59} Limited accessibility and availability of mental health services for patients with cancer is one reason why the proportion of patients seeking these services may be low.\textsuperscript{59} In addition, patients with cancer may not be interested in reporting psychological distress to their healthcare providers,\textsuperscript{59} or receiving psycho-oncological services for psychological distress.\textsuperscript{37}

**CONCLUSIONS**

Anxiety, depression, and stress reaction/adjustment disorder are common among patients with newly diagnosed breast cancer and are significantly associated with increased HCRU and expenditures in the first year following breast cancer diagnosis. Patients with breast cancer who experienced incident anxiety, depression, or stress reaction/adjustment disorder had higher all-cause healthcare costs in the year following their cancer diagnosis than those with prevalent anxiety, depression, or stress reaction/adjustment disorder or none of these psychiatric disorders. Early diagnosis and optimized management of anxiety, depression, and stress reaction/adjustment disorder in this vulnerable population could improve clinical outcomes and reduce HCRU and healthcare costs.

**Acknowledgments:** Manuscript writing support was provided by Shilpa Chennakrishnaiah, PhD, and Elizabeth Hubscher, PhD, from Cytel, Inc., which was funded by Blue Note Therapeutics, Inc.

**Disclosures:** D.D. and H.C. report employment by CVS Health Corp., Woonsocket, Rhode Island, which conducted research funded by Blue Note Therapeutics, Inc. S.Z. and M.M. report employment by and stock in Blue Note Therapeutics, Inc.

**Funding:** This study was supported by Blue Note Therapeutics, Inc. Manuscript writing support was provided by Shilpa Chennakrishnaiah, PhD, and Elizabeth Hubscher, PhD, from Cytel, Inc., which was funded by Blue Note Therapeutics, Inc.

**REFERENCES**


35. Zimmermann-Schlegel V, Hartmann M, Sklenarova H, Herzog W, Haun MW. Accessibility, availability, and potential benefits of psycho-oncology services: the perspective of community-
